Dr. Līga Bērziņa

Dr. Līga Bērziņa is a medical oncologist at Riga East Clinical University Hospital — Latvia's oncology center of excellence affiliated with Riga Stradins University. With 15 years of clinical experience, she has developed expertise in breast and thoracic oncology and immunotherapy.

She completed an advanced oncology fellowship at the Uppsala University Hospital in Sweden, one of the Nordic region's leading cancer centers. Sweden's strong oncology research tradition and close Nordic-Baltic ties made Uppsala a natural training destination, and Dr. Bērziņa brought Scandinavian oncology protocols back to Latvian practice.

She is an active ESMO member and participates in Baltic oncology research networks. She has been involved in clinical trial programs at Riga East, giving Latvian patients access to investigational therapies. She is committed to implementing molecular profiling-guided treatment and to advancing precision oncology in Latvia.

Dr. Bērziņa is known for her thoroughness, her evidence-based approach, and her clear patient communication in Latvian, Russian, and English.

Dr. Bērziņa received her MD from Riga Stradins University Faculty of Medicine in 2006. She completed her oncology residency at Riga East Clinical University Hospital and undertook an advanced oncology fellowship at Uppsala University Hospital, Sweden (2011–2012). Her PhD from Riga Stradins University in 2015 focused on immunotherapy biomarkers in non-small cell lung cancer. She is an ESMO member and is certified by the Latvian Medical Association in clinical oncology.

Dr. Bērziņa's primary clinical focus is breast and lung oncology. She designs and administers chemotherapy, targeted therapy (HER2-directed agents, EGFR/ALK inhibitors for lung cancer, CDK4/6 inhibitors for breast cancer), and immune checkpoint inhibitor regimens. She integrates NGS molecular profiling and PD-L1 testing into treatment planning. She also treats colorectal, ovarian cancer, and melanoma and participates in clinical trial protocols. She manages the multidisciplinary tumor board reviews at Riga East.

Dr. Bērziņa has published over 15 peer-reviewed articles in journals including Lung Cancer and the European Journal of Cancer. Her research focuses on immunotherapy biomarkers in lung cancer, breast cancer outcomes in the Latvian population, and precision oncology implementation in Baltic healthcare systems. She collaborates with oncologists in Sweden and participates in Baltic and Nordic oncology research consortia.

Dr. Bērziņa speaks Latvian, Russian, and English and is experienced in providing oncology second opinions and treatment to international patients. Riga East Hospital provides English and Russian-language consultation reports. Video consultations are available for second opinions. Latvia's EU membership ensures access to all EMA-approved cancer therapies at Baltic pricing levels.

Dr. Bērziņa received the Latvian Society of Oncology Young Investigator Award in 2016. She was recognized by Riga East Clinical University Hospital for her contributions to the lung cancer molecular profiling program. She has received ESMO travel grants and has been a presenter at Baltic oncology meetings.